

Robert J De Knegt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7628837/publications.pdf>

Version: 2024-02-01

186
papers

7,532
citations

66343

42
h-index

58581

82
g-index

190
all docs

190
docs citations

190
times ranked

9912
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2584.	7.4	1,327
2	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). <i>Ultraschall in Der Medizin</i> , 2017, 38, e16-e47.	1.5	659
3	Objectives, design and main findings until 2020 from the Rotterdam Study. <i>European Journal of Epidemiology</i> , 2020, 35, 483-517.	5.7	314
4	Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. <i>Hepatology</i> , 2008, 47, 1856-1862.	7.3	262
5	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2017, 66, 485-493.	3.7	225
6	Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 325-336.	8.1	208
7	Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. <i>Gut</i> , 2015, 64, 1289-1295.	12.1	178
8	Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment. <i>Journal of Infectious Diseases</i> , 2016, 213, 216-223.	4.0	145
9	Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. <i>Journal of Hepatology</i> , 2010, 52, 315-321.	3.7	132
10	The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm – volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 26-45.	2.0	117
11	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2022, 75, 219-228.	7.3	107
12	Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trial. <i>Journal of Hepatology</i> , 2005, 43, 630-636.	3.7	97
13	Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study. <i>Gut</i> , 2019, 68, 1088-1098.	12.1	97
14	Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 515-517.e3.	1.3	96
15	EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Short Version). <i>Ultraschall in Der Medizin</i> , 2017, 38, 377-394.	1.5	93
16	Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 6-25.	2.0	92
17	Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 867-876.	3.7	88
18	Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. <i>Hepatology</i> , 2015, 61, 471-480.	7.3	80

#	ARTICLE	IF	CITATIONS
19	Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan [®] predicts the absence of significant liver fibrosis. <i>Liver International</i> , 2007, 27, 639-645.	3.9	73
20	Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA. <i>Journal of Viral Hepatitis</i> , 2013, 20, 158-166.	2.0	73
21	Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. <i>Liver International</i> , 2012, 32, 622-628.	3.9	68
22	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , 2021, 74, 1053-1063.	3.7	68
23	Multiple biopsy passes and the risk of complications of percutaneous liver biopsy. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 36-41.	1.6	65
24	Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction. <i>Journal of Hepatology</i> , 2016, 64, 1274-1282.	3.7	64
25	Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. <i>Hepatology</i> , 2022, 75, 419-429.	7.3	64
26	Clinical implications of chronic hepatitis E virus infection in heart transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2013, 32, 78-85.	0.6	63
27	Frequencies of Circulating MAIT Cells Are Diminished in Chronic HCV, HIV and HCV/HIV Co-Infection and Do Not Recover during Therapy. <i>PLoS ONE</i> , 2016, 11, e0159243.	2.5	63
28	Randomized placebo controlled phase I/II trial of Î±-galactosylceramide for the treatment of chronic hepatitis C. <i>Journal of Hepatology</i> , 2007, 47, 356-365.	3.7	62
29	Epidemiology and management of chronic hepatitis E infection in solid organ transplantation: a comprehensive literature review. <i>Reviews in Medical Virology</i> , 2013, 23, 295-304.	8.3	61
30	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1821-1830.e6.	4.4	61
31	Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the non-overlap groups. <i>Liver International</i> , 2022, 42, 277-287.	3.9	60
32	Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100350.	4.9	52
33	CD4+CXCR5+ T cells in chronic HCV infection produce less IL-21, yet are efficient at supporting B cell responses. <i>Journal of Hepatology</i> , 2015, 62, 303-310.	3.7	51
34	Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. <i>Hepatology</i> , 2010, 52, 1225-1231.	7.3	50
35	Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 538-544.	8.1	49
36	Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2011, 46, 962-972.	1.5	48

#	ARTICLE	IF	CITATIONS
37	Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. <i>Frontiers in Immunology</i> , 2017, 8, 621.	4.8	48
38	Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2. <i>Journal of Viral Hepatitis</i> , 2015, 22, 46-73.	2.0	47
39	Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. <i>Journal of Hepatology</i> , 2010, 53, 455-459.	3.7	46
40	Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON). <i>Journal of Infectious Diseases</i> , 2017, 215, 1085-1093.	4.0	46
41	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1168-1176.	2.8	44
42	Crigler-Najjar syndrome in The Netherlands: Identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants. <i>Human Mutation</i> , 2010, 31, 52-59.	2.5	43
43	HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 856-864.	8.1	43
44	Microbiomics, Metabolomics, Predicted Metagenomics, and Hepatic Steatosis in a Population-Based Study of 1,355 Adults. <i>Hepatology</i> , 2021, 73, 968-982.	7.3	43
45	Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies. <i>Drugs</i> , 2015, 75, 1981-1992.	10.9	42
46	Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon alfa-2a and ribavirin for chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1306-1317.	3.7	40
47	Mucosal-associated invariant T cell frequency and function in blood and liver of HCV and HCV/HIV co-infected patients with advanced fibrosis. <i>Liver International</i> , 2018, 38, 458-468.	3.9	39
48	Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome. <i>Human Gene Therapy</i> , 2019, 30, 1297-1305.	2.7	39
49	Retention of CD4 ⁺ CD25 ⁺ FoxP3 ⁺ Regulatory T Cells in the Liver after Therapy-Induced Hepatitis C Virus Eradication in Humans. <i>Journal of Virology</i> , 2011, 85, 5323-5330.	3.4	38
50	Mucosal-Associated Invariant T Cells Are More Activated in Chronic Hepatitis B, but Not Depleted in Blood: Reversal by Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2017, 216, 969-976.	4.0	37
51	Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations. <i>Clinical Pharmacokinetics</i> , 2014, 53, 409-427.	3.5	35
52	Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population. <i>European Journal of Epidemiology</i> , 2020, 35, 1069-1085.	5.7	35
53	Epigenome-wide association meta-analysis of DNA methylation with coffee and tea consumption. <i>Nature Communications</i> , 2021, 12, 2830.	12.8	35
54	Antiviral activity of nardaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. <i>Hepatology</i> , 2010, 52, 1590-1599.	7.3	34

#	ARTICLE	IF	CITATIONS
55	Early treatment of acute hepatitis C infection is cost-effective in HIV-infected men-who-have-sex-with-men. PLoS ONE, 2019, 14, e0210179.	2.5	32
56	Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infectious Diseases, 2015, 15, 371.	2.9	31
57	How to diagnose and manage hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2016, 28, 146-152.	1.6	31
58	?-Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-?2b in chronic hepatitis C non-responders. Liver International, 2007, 27, 070816165951003-???	3.9	30
59	Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterology, 2012, 12, 11.	2.0	30
60	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. Gut, 2015, 64, 322-331.	12.1	30
61	Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation. Clinical Infectious Diseases, 2017, 65, 680-683.	5.8	30
62	The impact of <i><sc>PNPLA</sc>3</i> (<i>rs738409</i> C>G) polymorphisms on liver histology and long-term clinical outcome in chronic hepatitis B patients. Liver International, 2015, 35, 438-447.	3.9	29
63	Adherence to quality criteria improves concordance between transient elastography and ElastPQ for liver stiffness assessmentâ€”A multicenter retrospective study. Digestive and Liver Disease, 2018, 50, 1056-1061.	0.9	29
64	Serum Markers and Intestinal Mucosal Injury in Chronic Gastrointestinal Ischemia. Digestive Diseases and Sciences, 2011, 56, 506-512.	2.3	28
65	Polymorphisms of <i><sc>HLA</sc>â€œ<sc>DP</sc></i> are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2014, 40, 811-818.	3.7	28
66	Drugâ€”Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications. Clinical Pharmacokinetics, 2016, 55, 1471-1494.	3.5	27
67	The Intrahepatic T Cell Compartment Does Not Normalize Years After Therapy-Induced Hepatitis C Virus Eradication. Journal of Infectious Diseases, 2015, 212, 386-390.	4.0	26
68	Point Shear Wave Elastography by Acoustic Radiation Force Impulse Quantification in Comparison to Transient Elastography for the Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C: A Prospective International Multicenter Study. Ultraschall in Der Medizin, 2015, 36, 239-247.	1.5	25
69	Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. Alimentary Pharmacology and Therapeutics, 2020, 52, 1399-1406.	3.7	25
70	Insulin-like growth factor-I in liver cirrhosis. Journal of Hepatology, 1997, 27, 1133-1138.	3.7	24
71	Non-invasive measurement of liver fibrosis: Application of the FibroScanÂ® in hepatology. Scandinavian Journal of Gastroenterology, 2006, 41, 85-88.	1.5	24
72	Potent Immune Activation in Chronic Hepatitis C Patients upon Administration of An Oral Inducer of Endogenous Interferons that Acts via Toll-Like Receptor 7. Antiviral Therapy, 2012, 17, 657-667.	1.0	24

#	ARTICLE	IF	CITATIONS
73	Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE score. <i>Journal of Viral Hepatitis</i> , 2017, 24, 1023-1031.	2.0	24
74	The Path to Cancer and Back. <i>Transplantation</i> , 2017, 101, 910-915.	1.0	23
75	Association of Nonalcoholic Fatty Liver Disease and Fibrosis With Incident Dementia and Cognition. <i>Neurology</i> , 2022, 99, .	1.1	23
76	Significant liver damage in patients with bleeding disorders and chronic hepatitis C: non-invasive assessment of liver fibrosis using transient elastography. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 25-30.	3.8	22
77	Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B antigen-positive chronic hepatitis B patients. <i>Clinical Microbiology and Infection</i> , 2016, 22, 571.e5-571.e9.	6.0	22
78	Telaprevir/boceprevir era: From bench to bed and back. <i>World Journal of Gastroenterology</i> , 2012, 18, 6183.	3.3	22
79	Gene Expression Profiling To Predict and Assess the Consequences of Therapy-Induced Virus Eradication in Chronic Hepatitis C Virus Infection. <i>Journal of Virology</i> , 2014, 88, 12254-12264.	3.4	21
80	NK cell phenotypic and functional shifts coincide with specific clinical phases in the natural history of chronic HBV infection. <i>Antiviral Research</i> , 2017, 140, 18-24.	4.1	21
81	The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 568-577.	2.0	19
82	Hepatitis C Core-Antigen Testing from Dried Blood Spots. <i>Viruses</i> , 2019, 11, 830.	3.3	19
83	Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 314-320.	3.7	19
84	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014, 61, 482-491.	3.7	18
85	Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF). <i>Antiviral Research</i> , 2016, 132, 70-75.	4.1	18
86	Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1156-1163.	2.0	17
87	Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study. <i>Hepatology</i> , 2023, 77, 585-593.	7.3	17
88	TLR7 polymorphism, sex and chronic HBV infection influence plasmacytoid DC maturation by TLR7 ligands. <i>Antiviral Research</i> , 2018, 157, 27-37.	4.1	16
89	ITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV Infection. <i>PLoS ONE</i> , 2015, 10, e0139317.	2.5	15
90	Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy. <i>Antiviral Research</i> , 2015, 123, 86-92.	4.1	15

#	ARTICLE	IF	CITATIONS
91	Diet-Dependent Acid Loadâ€”The Missing Link Between an Animal Proteinâ€”Rich Diet and Nonalcoholic Fatty Liver Disease?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6325-6337.	3.6	14
92	Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring. <i>Journal of Hepatology</i> , 2019, 70, 552-554.	3.7	14
93	Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1933-1940.e1.	4.4	14
94	Cost Utility of Telaprevirâ€”PR (Peginterferonâ€”Ribavirin) Versus Boceprevirâ€”PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 647-659.	2.1	13
95	Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients. <i>Journal of Clinical Virology</i> , 2019, 114, 1-5.	3.1	13
96	Long-term effect of treatment of acute Budd-Chiari syndrome with a transjugular intrahepatic portosystemic shunt. <i>Hepatology</i> , 2002, 35, 1551-1552.	7.3	12
97	Can point shear wave elastography differentiate focal nodular hyperplasia from hepatocellular adenoma. <i>Journal of Clinical Ultrasound</i> , 2018, 46, 380-385.	0.8	12
98	Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease â€” implications for the clinical utility of the EASL NIT guideline. <i>Journal of Hepatology</i> , 2022, 76, 245-246.	3.7	12
99	Pharmacokinetics and Antiviral Activity of Phx1766, a Novel HCV Protease Inhibitor, Using An Accelerated Phase I Study Design. <i>Antiviral Therapy</i> , 2012, 17, 365-375.	1.0	11
100	Hepatitis A related acute liver failure by consumption of contaminated food. <i>Journal of Clinical Virology</i> , 2014, 61, 456-458.	3.1	11
101	Gene expression profiling of human tissueâ€”resident immune cells: Comparing blood and liver. <i>Journal of Leukocyte Biology</i> , 2019, 105, 603-608.	3.3	11
102	Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1967-1973.	4.0	11
103	Negative Regulation of Hepatitis C Virus Specific Immunity Is Highly Heterogeneous and Modulated by Pegylated Interferon-Alpha/Ribavirin Therapy. <i>PLoS ONE</i> , 2012, 7, e49389.	2.5	11
104	Analysis of the transcriptome and immune function of monocytes during IFNÎ±-based therapy in chronic HCV revealed induction of TLR7 responsiveness. <i>Antiviral Research</i> , 2014, 109, 116-124.	4.1	10
105	Inosine triphosphate pyrophosphohydrolase activity: more accurate predictor for ribavirin-induced anemia in hepatitis C infected patients than ITPA genotype. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 2021-9.	2.3	10
106	Flares during longâ€”term entecavir therapy in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1882-1887.	2.8	10
107	A Model-Based Prediction of the Probability ofâ€”Hepatocellularâ€”Adenoma and Focal Nodular Hyperplasiaâ€”Basedâ€”on Characteristics on Contrast-Enhancedâ€”Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2017, 43, 2144-2150.	1.5	10
108	Serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) predict severity of liver disease in chronic hepatitis B. <i>Clinical and Experimental Gastroenterology</i> , 2017, Volume 10, 203-209.	2.3	9

#	ARTICLE	IF	CITATIONS
109	The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030. <i>Journal of Clinical Medicine</i> , 2021, 10, 4562.	2.4	9
110	Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 432-442.	3.7	9
111	Psychiatric Side Effects and Fluctuations in Serotonergic Parameters in the Treatment of Chronic Hepatitis C Infection. <i>Neuropsychobiology</i> , 2012, 65, 126-132.	1.9	8
112	Activated CD4+ T Cells and Highly Differentiated Alloreactive CD4+ T Cells Distinguish Operationally Tolerant Liver Transplantation Recipients. <i>Liver Transplantation</i> , 2022, 28, 98-112.	2.4	8
113	Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0161821.	2.5	8
114	Disease burden and management of Crigler-Najjar syndrome: Report of a world registry. <i>Liver International</i> , 2022, 42, 1593-1604.	3.9	8
115	The transition from NAFLD to MAFLD: One size still does not fit all—Time for a tailored approach?. <i>Hepatology</i> , 2022, 76, 1243-1245.	7.3	8
116	Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2022, 227, 113-122.	4.0	8
117	Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques. <i>Obesity Reviews</i> , 2022, 23, .	6.5	7
118	Natural killer cell activity and function in chronic HCV-infected patients during peg interferon and ribavirin: Early effects of active substance use. <i>Antiviral Research</i> , 2013, 97, 347-355.	4.1	6
119	Prominent HLA-G Expression in Liver Disease But Not After Liver Transplantation. <i>Transplantation</i> , 2015, 99, 2514-2522.	1.0	6
120	Interferon-free antiviral therapy for chronic hepatitis C among patients in the liver transplant setting. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 219-225.	2.4	6
121	Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls. <i>Journal of Infectious Diseases</i> , 2020, 224, 443-452.	4.0	6
122	NAFLD-Related Hepatocellular Carcinoma and the Four Horsemen of the Apocalypse. <i>Hepatology</i> , 2020, 71, 774-776.	7.3	6
123	Sex-specific normal values and determinants of infrarenal abdominal aortic diameter among non-aneurysmal elderly population. <i>Scientific Reports</i> , 2021, 11, 17762.	3.3	6
124	Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 183-195.	8.9	6
125	Hepatitis C Elimination in the Netherlands (CELINE): How nationwide retrieval of lost to follow-up hepatitis C patients contributes to micro-elimination. <i>European Journal of Internal Medicine</i> , 2022, 101, 93-97.	2.2	6
126	Ezetimibe: A biomarker for efficacy of liver directed UGT1A1 gene therapy for inherited hyperbilirubinemia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1223-1229.	3.8	5

#	ARTICLE	IF	CITATIONS
127	P0661 : Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: Results from a large european multi-center study. <i>Journal of Hepatology</i> , 2015, 62, S568.	3.7	5
128	Immunosuppressive drug withdrawal late after liver transplantation improves the lipid profile and reduces infections. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1444-1451.	1.6	5
129	Telaprevir for Chronic HCV Infection. <i>New England Journal of Medicine</i> , 2009, 361, 533-535.	27.0	4
130	Safety and antiviral activity of JTK-652: a novel HCV infection inhibitor. <i>Antiviral Therapy</i> , 2010, 15, 765-773.	1.0	4
131	Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1057-1064.	2.8	4
132	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1851-1859.	2.8	4
133	Effects of Escitalopram Prophylaxis During Antiviral Treatment for Chronic Hepatitis C in Patients With a History of Intravenous Drug Use and Depression. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 1069-1077.	2.2	4
134	Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 539-547.	3.7	3
135	Continuous Interferon- β Infusion in Combination with Ribavirin for Chronic Hepatitis C in Treatment-Experienced Patients. <i>Antiviral Therapy</i> , 2012, 17, 509-517.	1.0	3
136	504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS. <i>Journal of Hepatology</i> , 2013, 58, S207.	3.7	3
137	Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients. <i>Antiviral Research</i> , 2013, 98, 469-475.	4.1	3
138	Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections. <i>Journal of Hepatology</i> , 2014, 60, 231-232.	3.7	3
139	Safety of Direct-Acting Antivirals-Based Therapy for the Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis: Results from an International Multicenter Cohort Study. <i>Journal of Hepatology</i> , 2016, 64, S812-S813.	3.7	3
140	High Risk of Infection During Triple Therapy with First- Generation Protease Inhibitors: A Nationwide Cohort Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 197-204.	0.9	3
141	The European Prevalence of Resistance Associated Substitutions among Direct Acting Antiviral Failures. <i>Viruses</i> , 2022, 14, 16.	3.3	3
142	Natural History of HCV-induced Liver Disease. <i>Current Hepatitis Reports</i> , 2013, 12, 251-260.	0.3	2
143	The ARRIBA concept: adequate resorption of ribavirin. <i>Antiviral Therapy</i> , 2015, 20, 515-520.	1.0	2
144	Ribavirin steady-state plasma level is a predictor of sustained virological response in hepatitis C-infected patients treated with direct-acting antivirals. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 864-872.	3.7	2

#	ARTICLE	IF	CITATIONS
145	Younger age and language barriers are associated with nonadherence to clinical follow-up in hepatitis B treatment. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1216-1219.	2.0	2
146	Editorial: rapid disease progression in hepatitis delta—can we turn the tide?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 172-173.	3.7	2
147	Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon- α /ribavirin combination therapy after 4 weeks of treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1.	1.6	2
148	Current therapy of hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 65-69.	1.5	1
149	941 JTK-652 IS A NOVEL HCV ENTRY INHIBITOR: RESULTS OF A PHASE 1 STUDY EVALUATING SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY IN CHRONIC HEPATITIS C PATIENTS. <i>Journal of Hepatology</i> , 2009, 50, S342.	3.7	1
150	The Pan-Genotypic Costs-Effectiveness Of Sofosbuvir in Hepatitis C Virus. <i>Value in Health</i> , 2014, 17, A676.	0.3	1
151	Costs Per Successfully Treated Patient with Sofosbuvir in GT1 HCV. <i>Value in Health</i> , 2014, 17, A673.	0.3	1
152	Cost-Effectiveness of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Patients With Chronic Hcv in the Netherlands. <i>Value in Health</i> , 2015, 18, A588.	0.3	1
153	High-dose (peg)interferon therapy in treatment-naïve, interleukin-28B rs12979860 CT/TT genotype 1 chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2015, 47, 87-88.	0.9	1
154	HCV treatment in liver transplantation: timing is the challenge. <i>Transplant International</i> , 2016, 29, 1067-1069.	1.6	1
155	Characterization of the intrahepatic immune response of virally-suppressed chronic hepatitis B patients to treatment with the oral TLR7 agonist GS-9620. <i>Journal of Hepatology</i> , 2017, 66, S478-S479.	3.7	1
156	Current Tolerance-Associated Peripheral Blood Gene Expression Profiles After Liver Transplantation Are Influenced by Immunosuppressive Drugs and Prior Cytomegalovirus Infection. <i>Frontiers in Immunology</i> , 2021, 12, 738837.	4.8	1
157	Tamoxifen use and potential effects on liver parenchyma: A long-term prospective transient elastographic evaluation. <i>Hepatology Communications</i> , 2022, 6, 2565-2568.	4.3	1
158	P1889 Pharmacokinetic profiles in chronic hepatitis C patients treated with high-dose pegylated interferon. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, S541-S542.	2.5	0
159	Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon- α /ribavirin treatment for chronic hepatitis C. <i>Antiviral Therapy</i> , 2011, 16, 771-774.	1.0	0
160	IL28B polymorphism and hepatitis C: A genetic marker of peginterferon- α sensitivity devoid from classical interferon- α side effects?. <i>Journal of Hepatology</i> , 2012, 56, 741-742.	3.7	0
161	P1211 HIGH DOSE RIBAVIRIN INFLUENCES EARLY VIRAL KINETICS AND IMPROVES SVR RATES IN CHRONIC HCV PATIENTS WHO ADHERE TO THERAPY (VIRID STUDY). <i>Journal of Hepatology</i> , 2014, 60, S492.	3.7	0
162	Living donor liver transplantation in HCV-infected patients: improvement of the donor risk-recipient benefit ratio is around the corner. <i>Transplant International</i> , 2014, 27, 765-766.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Epidemiological Trends among the Population with Chronic HCV Infection in the Netherlands. <i>Antiviral Therapy</i> , 2016, 21, 207-215.	1.0	0
164	Cost Per Patient With Sustained Viral Response for Ombitasvir/Paritaprevir/Ritonavir And Dasabuvir With or Without Ribavirin In Genotype 1 Patients With Chronic Hcv In The Netherlands. <i>Value in Health</i> , 2015, 18, A586.	0.3	0
165	P0613 : Hepatitis B core related antigen may be a marker for immune control in HBeAg negative chronic hepatitis B infection. <i>Journal of Hepatology</i> , 2015, 62, S547.	3.7	0
166	P0690 : IFN-free therapy for chronic HCV: Transcriptomics and NK cell analyses. <i>Journal of Hepatology</i> , 2015, 62, S581.	3.7	0
167	P0695 : Triple therapy for chronic HCV patients induces early activation of intrahepatic NK cells. <i>Journal of Hepatology</i> , 2015, 62, S583.	3.7	0
168	P0761 : Epidemiological trends among patients with chronic HCV infection in a tertiary centre in the Netherlands. <i>Journal of Hepatology</i> , 2015, 62, S614.	3.7	0
169	Polymorphisms of HLA-DPB1 are Associated with Long-Term Clinical Outcome in a Diverse Cohort of Chronic Hepatitis B Patients. <i>Journal of Hepatology</i> , 2016, 64, S380.	3.7	0
170	NK Cells from Chronic HBV Patients in Different Clinical Phase Exhibit Altered Gene Expression Profiles by RNA-SEQ. <i>Journal of Hepatology</i> , 2016, 64, S384-S385.	3.7	0
171	Sustained Virological Response Results in Regression of Liver Stiffness in Patients with Chronic Hepatitis C Virus Infection. <i>Journal of Hepatology</i> , 2016, 64, S731.	3.7	0
172	Similar Frequencies, Phenotype and Activation Status of Intrahepatic NK Cells in Chronic HBV Patients after Long-Term Treatment with Tenofovir Disoproxil Fumarate (TDF). <i>Journal of Hepatology</i> , 2016, 64, S389-S390.	3.7	0
173	Do Mucosal-Associated Invariant T (Mait) Cells Impact Fibrosis in HCV and HIV/HCV Co-Infected Patients?. <i>Journal of Hepatology</i> , 2016, 64, S509.	3.7	0
174	MAIT cell frequency and function in blood and liver of hepatitis C virus mono- and hepatitis C virus/human immunodeficiency virus co-infected patients with mild versus advanced fibrosis. <i>Journal of Hepatology</i> , 2017, 66, S326-S327.	3.7	0
175	Why should dermatologists think of liver fibrosis?. <i>British Journal of Dermatology</i> , 2017, 177, 610-611.	1.5	0
176	Clinical evaluation of hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, S480.	3.7	0
177	Gender differences in body composition in lean and overweight non-alcoholic fatty liver disease: The Rotterdam Study. <i>Journal of Hepatology</i> , 2018, 68, S555.	3.7	0
178	Serum immune signatures predict HCC development in DAA-treated HCV patients. <i>Journal of Hepatology</i> , 2018, 68, S528.	3.7	0
179	Therapeutic Drug Monitoring of DAAs overcomes contraindications against anti-epileptics in HCV treatment (HepNed003). <i>Journal of Hepatology</i> , 2018, 68, S288-S289.	3.7	0
180	FRI-163-Reduced liver-related complications after 13 years of follow-up of interferon-alpha treatment for HBeAg-positive chronic hepatitis B: The ELITE-B study. <i>Journal of Hepatology</i> , 2019, 70, e460.	3.7	0

#	ARTICLE	IF	CITATIONS
181	THU-169-Genotype 4 RAS patterns in a European hepatitis C cohort. <i>Journal of Hepatology</i> , 2019, 70, e236.	3.7	0
182	FRI-206-Relationship between hepatitis B core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleos (t)ide analogues. <i>Journal of Hepatology</i> , 2019, 70, e484.	3.7	0
183	Reply to: "Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population". <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	4.4	0
184	Editorial: HBV cure"the quest for biomarkers to predict off-treatment sustained response. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 555-556.	3.7	0
185	Discrepancy between NAFLD and MAFLD " is it only due to misclassification of MAFLD?. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	4.4	0
186	Reply to: "Etelpragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD". <i>Hepatology Communications</i> , 2022, 6, 2605-2606.	4.3	0